Sihuan Pharma wins approval for Phase I to III trial of EGFR inhibitor
Category: #health  By Paroma Bhattacharya  Date: 2019-05-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sihuan Pharma wins approval for Phase I to III trial of EGFR inhibitor

Sihuan Pharmaceutical Holdings Group, a leading cardio-cerebral vascular drug maker in prescription drug industry of China, has recently confirmed that the third generation of EGFR inhibitor XZP-5809 has been awarded drug clinical trial approval by the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC).

XZP-5809 is reportedly a novel category 1 drug being developed by Sihuan Pharmaceutical. Apparently, the new drug is an innovative third generation EGFR-TKI that can be taken orally and has a strong capability for targeting. It features established mechanism, innovative structure, and irreversible binding to EGFR. The drug has improved selection with lower activity for wild-type EGFR and against gene-mutation EGFR, it demonstrated higher activity.

Sources close to the matter informed that the New Drug has unique advantages in its safety and activity, based on the data accumulated from the completed preclinical trial, as compared with products of the same type. Against wild-type EGFR, the New Drug as well as its metabolite showed lower activity. Owing to worldwide competitive advantage and a higher safety profile, the New Drug could become a novel treatment option for cancer patients.

According to CEO and Chairman of Sihuan Pharmaceutical Holdings, Dr. Che Fengsheng, noteworthy progress has been made in the area of lung cancer treatment, including anti-cancer immunotherapy. However, for non-small cell lung cancer with EGFR mutation, targeted therapy is still considered the prime choice, Dr. Fengsheng said.

Seemingly, the toxicological and preclinical pharmacodynamic data show that the features of the New Drug include good efficacy against acquired resistance mutations and against EGFR sensitive mutations, potential clinical efficacy for patients suffering with lung cancer brain metastasis. It also has reduced impact on cardiac function and better safety profile when compared to drugs of the same type in the market.

The clinical indication for the New Drug candidate is likely to be solid tumors, like metastatic or locally advanced lung cancer with acquired resistance mutations and EGFR-sensitive mutations, sources added.

Source Credit: https://www.prnewswire.com/news-releases/sihuan-pharm-obtained-phase-i-to-iii-clinical-trial-approval-for-the-third-generation-of-egfr-inhibitor-xzp-5809-300857919.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Suning.com acquires Carrefour China for expanding FMCG operations
Suning.com acquires Carrefour China for expanding FMCG operations
By Paroma Bhattacharya

Suning.com, one of the largest non-government retailers in China, recently announced that it will buy an equity stake of 80% in Carrefour China, the local division of the biggest retailer in Europe, for 620 million Eur...

Shopify introduces AI-powered fulfillment network for SMB partners
Shopify introduces AI-powered fulfillment network for SMB partners
By Paroma Bhattacharya

Shopify, an e-commerce SaaS provider has reportedly introduced an AI powered fulfillment network for its merchants as the company is working to differentiate its product portfolio from other industry contenders.

<...

Pinterest unveils new partner program to boost shopping experiences
Pinterest unveils new partner program to boost shopping experiences
By Paroma Bhattacharya

Pinterest has reportedly rebranded its Pinterest Marketing Partners program into the global Pinterest Partner program, as it turns to third parties to introduce shopping experiences onto its platform.